SCHEMBL832345

SCHEMBL832345

CS(=O)(=O)Nc1cccc(S(=O)(=O)NC(=O)c2c(-c3ccccc3F)c3cc(Cl)ccc3n2Cc2ccccc2F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.40
MAPT P10636 6/20 0.39
MEN1 O00255 2/20 0.39
LMNA P02545 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
ECE1 P42892 1/20 0.38
SERPINE1 P05121 2/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
POLB P06746 1/20 0.37
NPY1R P25929 1/20 0.37
NPY2R P49146 1/20 0.37
LOXL2 Q9Y4K0 1/20 0.36
TP53 P04637 1/20 0.36
FLT1 P17948 2/20 0.36
FLT4 P35916 2/20 0.36
KDR P35968 2/20 0.36
PARG Q86W56 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL832302 0.91 PPARG (0.40) PPARGMAPTMEN1LMNAKMT2A
SCHEMBL862574 0.91 CYP2C8 (0.41) PPARGMAPTMEN1LMNAKMT2A
SCHEMBL862454 0.85 CYP2C8 (0.39) PPARGMAPTKMT2ASERPINE1LOXL2
SCHEMBL862590 0.85 CYP2C8 (0.39) PPARGMAPTMEN1LMNAKMT2A
SCHEMBL862901 0.84 CYP2C8 (0.39) PPARGMAPTMEN1LMNAKMT2A
SCHEMBL862460 0.84 CYP2C8 (0.41) PPARGKMT2ASERPINE1PTGDR2LOXL2
SCHEMBL862580 0.83 CYP2C8 (0.38) PPARGKMT2ASERPINE1PTGDR2LOXL2
SCHEMBL862329 0.83 PPARG (0.40) PPARGKMT2ASERPINE1LOXL2FLT1
SCHEMBL862708 0.82 CYP2C8 (0.38) PPARGMAPTMEN1LMNAKMT2A
SCHEMBL862184 0.82 PPARG (0.39) PPARGMEN1KMT2AECE1SERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 PPARG 4093/4885MAPT 1047/4885MEN1 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.